



Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Audited Annual Financial Statements

for the year ended 31 December 2025

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Annual Financial Statements
for the year ended 31 December 2025

<i>Contents</i>	Page
Directors' responsibility statement	2
Trustee's report	3 - 4
Independent auditor's report	5 - 8
Statement of financial position	9
Statement of profit or loss and other comprehensive income	10
Statement of changes in net assets attributable to holders of redeemable securities	11
Statement of cash flows	12
Notes to the financial statements	13 - 23

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Directors' responsibility statement

for the year ended 31 December 2025

The directors of Sygnia Itrix (RF) Proprietary Limited (the Manager) are responsible for the preparation and fair presentation of the financial statements of the Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund (the Fund), comprising the statement of financial position at 31 December 2025, and the statement of profit or loss and other comprehensive income, statement of changes in net assets attributable to holders of redeemable securities and statement of cash flows for the year then ended, and notes to the financial statements. These include a summary of significant accounting policies and other explanatory notes, in accordance with IFRS[®] Accounting Standards issued by the International Accounting Standards Board ("IASB"), Financial Reporting Pronouncements as issued by Financial Reporting Standards Council and in the manner required by:

- The Collective Investment Schemes Control Act; and
- The Trust Deed.

The directors of the Manager, whose names are stated below, hereby confirm that –

- (a) the annual financial statements set out on pages 9 to 23, fairly present in all material respects the financial position, financial performance and cash flows of the Fund in terms of IFRS Accounting Standards;
- (b) to the best of our knowledge and belief, no facts have been omitted or untrue statements made that would make the financial statements false or misleading;
- (c) internal financial controls have been put in place to ensure that material information relating to the Fund have been provided to effectively preparer of the financial statements of the Fund;
- (d) the internal financial controls are adequate and effective and can be relied upon in compiling the annual financial statements, having fulfilled our role and function within the combined assurance model pursuant to principle 15 of the King IV[™] Code;
- (e) where we are not satisfied, we have disclosed to the audit committee and the auditors the deficiencies in design and operational effectiveness of the internal financial controls and any fraud that involves directors, and have taken the necessary remedial action; and
- (f) we are not aware of any fraud involving the directors of the Manager.

The directors of the Manager have made an assessment of the ability of the Fund to continue as a going concern and have no reason to believe that the Fund will not be a going concern in the year ahead.


The auditor is responsible for reporting on whether the financial statements are fairly presented in accordance with the applicable financial reporting framework.

Approval of the annual financial statements

The annual financial statements of Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund as identified in the first paragraph, were approved by the directors of Sygnia Itrix (RF) Proprietary Limited on 13 March 2026 and are signed on their behalf by:



RA Ismail



I Madjarova



The Manager
Sygnia Itrix (RF)(PTY) Limited
7th Floor, The Foundry
Cardiff Street
Green Point
Cape Town
8001

REPORT OF THE TRUSTEE FOR SYGNIA ITRIX COLLECTIVE INVESTMENT SCHEME

We, the Standard Bank of South Africa Limited, in our capacity as Trustee of the Sygnia Itrix Collective Investment Scheme (“the Scheme”) have prepared a report in terms of Section 70(1)(f) of the Collective Investment Schemes Control Act, 45 of 2002, as amended (“the Act”), for the financial year ended 31 December 2025.

In support of our report we have adopted certain processes and procedures that allow us to form a reasonable conclusion on whether the Manager has administered the Scheme in accordance with the Act and the Scheme Deed.

As Trustees of the Scheme we are also obliged to in terms of Section 70(3) of the Act to satisfy ourselves that every statement of comprehensive income, statement of financial position or other return prepared by the Manager of the Scheme as required by [Section 90](#) of the Act fairly represents the assets and liabilities, as well as the income and distribution of income, of every portfolio of the Scheme.

The Manager is responsible for maintaining the accounting records and preparing the annual financial statements of the Scheme in conformity with IFRS Accounting Standards. This responsibility also includes appointing an external auditor to the Scheme to ensure that the financial statements are properly drawn up so as to fairly represent the financial position of every portfolio of its collective investment scheme are in accordance with IFRS Accounting Standards and in the manner required by the Act.

Our enquiry into the administration of the Scheme by the Manager does not cover a review of the annual financial statements and hence we do not provide an opinion thereon.

Based on our records, internal processes and procedures we report that nothing has come to our attention that causes us to believe that the accompanying financial statements do not fairly represent the assets and liabilities, as well as the income and distribution of income, of every portfolio of the Scheme administered by the Manager.

Standard Bank Centre 1st Floor 5 Simmonds Street Johannesburg 2001 PO Box 61690 Marshalltown 2107 South Africa
Tel. Switchboard: +27 (0)11 636 9112 www.standardbank.co.za

The Standard Bank of South Africa Limited (Reg. No. 1962/000738/06) Authorised financial services and registered credit provider (NCRCP15)

Directors: NMC Nyembezi (Chairman) DWP Hodnett* (Chief Executive Officer) LL Bam HJ Berrange PLH Cook A Daehnke* OA David-Borha¹ GJ Fraser-Moleketi GMB Kennealy BJ Kruger
Li Li² JH Maree NNA Matyumza RN Ogega³ Fenglin Tian²

Company Secretary: K Froneman - 2025/10/10

*Executive Director ¹ Nigerian ² Chinese ³ Kenyan

We confirm that according to the records available to us, no losses were suffered in the portfolios and no investor was prejudiced as a result thereof.

We conclude our report by stating that we reasonably believe that the Manager has administered the Scheme in accordance with:

- (i) the limitations imposed on the investment and borrowing powers of the manager by this Act;
- (ii) and the provisions of this Act and the deed;

Signed by: Hoosain
Signed at: 2026-03-13 10:02:23 +02:00
Reason: Witnessing Hoosain

Hoosain Hamdulay

Hoosain Hamdulay
Standard Bank of South Africa Limited

13 March 2026

Forvis Mazars, Rialto Road
Grand Moorings Precinct Century City, 7441
PO Box 134, Century City, 7446

Tel: +27 21 818 5000
Fax: +27 21 818 5001
Email: office.za.cpt@forvismazars.com

forvismazars.com/za



Independent Auditor's Report

31 December 2025

To the security investors of Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund (the Fund) set out on pages 9 to 23, which comprise the statement of financial position as at 31 December 2025, and the statement of profit or loss and other comprehensive income, statement of changes in net assets attributable to holders of redeemable securities and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund as at 31 December 2025, and its financial performance and cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and in the manner required by the Collective Investment Schemes Control Act of South Africa, and the manner required by the Trust Deed approved by the Financial Sector Conduct Authority.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Fund in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

In terms of the IRBA Rule on Enhanced Auditor Reporting for the Audit of Financial Statements of Public Interest Entities, published in Government Gazette No. 49309 dated 15 September 2023 (EAR Rule), we report:

Registered Auditor – A firm of Chartered Accountants (SA) • IRBA Registration Number 900222

Partners: MV Ninan (Country Managing Partner), C Abrahamse, SJ Adlam, JPMP Atwood, JM Barnard, AK Batt, S Beets, T Beukes, WI Blake, HL Burger, MJ Cassan, J Coetzee, JC Combrink, JR Comley, TVDL De Vries, CR De Wee, G Deva, Y Dockrat, S Doolabh, M Edelberg, JJ Eloff, T Erasmus, F Esterhuizen, Y Ferreira, MH Fisher, B Frey, T Gangen, M Groenewald, K Hoosain, MY Ismail, B Jansen, J Kasan, D Keeve, Z Khan, J Marais, TL Maree, N Mayat, B Mbunge, F Mohamed, G Molyneux, R Murugan, W Olivier, MT Rossouw, M Pieterse, E Pretorius, W Rabe, D Resnick, L Roeloffze, M Saayman, E Sibanda, MR Snow, M Steenkamp, EM Steyn, HH Swanepoel, AL Swartz, DM Tekie, MJA Teuchert, N Thelander, S Truter, R van Molendorff, JC Van Tubbergh, N Volschenk, S Vorster, J Watkins-Baker

Our offices: Bloemfontein, Cape Town, Durban, Gqeberha, Johannesburg, Paarl, Pretoria

Final Materiality

The nature, timing and extent of our audit procedures was influenced by our determination and application of materiality. We have quantitatively calculated the materiality threshold, based on our professional judgement, as detailed in the table below, factoring in any qualitative considerations. We have evaluated the effect of any misstatements noted during the audit on an individual and aggregate basis.

Financial statements	
Final materiality	R5,572,000
Basis for determining materiality	2.5% of net assets attributable to holders of redeemable securities have been used as the basis for determining final materiality.
Rational for the materiality benchmark applied	We selected net assets attributable to holders of redeemable securities as the materiality benchmark for the fund. This would be the benchmark that best reflects the value available to holders of redeemable securities on redemption at year-end and the best measure of the fund's performance and growth. We have selected 2.5% based on our professional judgement, which considers the regulatory environment the fund trades in as well as the reliance placed on the financial statements by the holders of redeemable securities.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. We have determined that there are no key audit matters to communicate in our report.

Other Information

The Manager's directors are responsible for the other information. The other information comprises the information included in the document titled "Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund Annual Financial Statements for the year ended 31 December 2025", which includes the Directors' Responsibility Statement and Trustees' Report. The other information does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Manager's Directors for the Financial Statements

The Manager's directors are responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and the requirements of the Collective Investment Schemes Control Act of South Africa, in the manner required by the Trust Deed approved by the Financial Sector Conduct Authority, and for such internal control as the Manager's directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Manager's directors are responsible for assessing the fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Manager's directors either intend to liquidate the fund or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the fund's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Manager's directors.
- Conclude on the appropriateness of the Manager's directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Manager's directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Manager's directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Manager's directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

Audit Tenure

In terms of the IRBA Rule published in Government Gazette Number 39475 dated 4 December 2015, we report that Forvis Mazars has been the auditor of the Fund for five years.

A handwritten signature in black ink that reads "Forvis Mazars".

Forvis Mazars
Partner: Mia Pieterse
Registered Auditor
13 March 2026
Cape Town

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Statement of financial position

as at 31 December 2025

	Notes	2025 R	2024 R
Assets			
Financial assets at fair value through profit or loss	** 4	222 676 036	559 540 966
Trade and other receivables	* 6	139 222	363 389
Cash and cash equivalents	* 7	1 150 526	2 432 081
Total assets		223 965 784	562 336 436
Liabilities			
Net assets attributable to holders of redeemable securities	***	222 919 160	559 969 324
Trade and other payables	* 8	1 046 624	2 367 112
Total liabilities		223 965 784	562 336 436

* Financial assets/liabilities measured at amortised cost

** Financial assets measured at fair value - mandatory

*** Financial liabilities at fair value - designated

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Statement of profit or loss and other comprehensive income

for the year ended 31 December 2025

	Notes	2025 R	2024 R
Income			
Investment income	10	7 628 364	13 440 931
Foreign exchange gain		90 294	-
Net gain on financial assets at fair value through profit or loss	9	24 275 587	-
		<u>31 994 245</u>	<u>13 440 931</u>
Expenses			
Foreign exchange loss		-	(135 127)
Management and administrative expenses	11	(3 185 582)	(4 780 204)
Net loss on financial assets at fair value through profit or loss	9	-	(2 387 082)
		<u>(3 185 582)</u>	<u>(7 302 413)</u>
Profit before distributions		28 808 663	6 138 518
Distributions	5.3	(3 157 599)	(6 405 761)
Profit/(loss) before tax		25 651 064	(267 243)
Withholding tax		(1 429 340)	(2 399 735)
Profit/(loss) for the year before translation adjustment		24 221 724	(2 666 978)
Translation of functional currency to ZAR	5.5	(45 462 253)	13 173 879
Total comprehensive (loss)/income and (decrease)/increase in net assets attributable to holders of redeemable securities		(21 240 529)	10 506 901

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Statement of changes in net assets attributable to holders of redeemable securities

for the year ended 31 December 2025

	Notes	Net assets attributable to holders of redeemable securities R
Balance at 1 January 2024		670 947 951
Loss for the year before translation adjustment		(2 666 978)
Creation of redeemable securities	5.2	111 725 064
Redemption of redeemable securities	5.2	(233 210 592)
Foreign currency translation adjustments attributable to holders of redeemable securities	5.5	13 173 879
Balance at 31 December 2024		<u>559 969 324</u>
Profit for the year before translation adjustment		24 221 724
Redemption of redeemable securities	5.2	(315 809 635)
Foreign currency translation adjustments attributable to holders of redeemable securities	5.5	(45 462 253)
Balance at 31 December 2025		<u>222 919 160</u>

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Statement of cash flows

for the year ended 31 December 2025

	Notes	2025 R	2024 R
Cash utilised in operations	12	(222 418)	(119 644)
Dividends received	10	6 333 410	10 723 424
Management fees paid	11	(2 153 930)	(3 907 207)
Interest received	10	26 279	60 388
Net cash inflow from operating activities		3 983 341	6 756 961
Cash inflow from investing activities		315 678 264	121 740 773
Net sales of index constituents	13	315 678 264	121 740 773
Cash outflow from financing activities		(321 033 454)	(128 800 214)
Proceeds on creation of securities	5.2	-	112 099 609
Payment on redemption of securities	5.2	(316 764 522)	(233 886 908)
Distributions paid to investors	5.3	(4 268 932)	(7 012 915)
Net decrease in cash and cash equivalents		(1 371 849)	(302 480)
Effects of exchange rate changes on the balance of cash		90 294	(135 127)
Cash and cash equivalents at the beginning of year		2 432 081	2 869 688
Cash and cash equivalents at the end of year	7	1 150 526	2 432 081

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

1. Reporting entity

Sygnia Itrix Health Innovation Actively Managed ETF (the Fund) is a Fund domiciled in South Africa. The address of the Fund's registered office is 7th floor The Foundry, Green Point, Cape Town, 8001, South Africa.

The Fund is actively managed with an objective to provide a simple investment vehicle to investors who want to achieve long term capital appreciation by gaining exposure to companies positioned at the forefront of healthcare innovation. The Fund's benchmark is Solactive Developed Markets Healthcare 150 Index which tracks the performance of the largest 150 companies from the Healthcare Industry and is based on the Solactive Global Benchmark Series.

Sygnia Itrix (RF) Proprietary Limited (the Manager) is the management company of the Fund. The investment activities, including the administration of the Fund, are managed by the Manager.

2. Basis of preparation

2.1 Basis of measurement

The financial statements are prepared on the historical cost basis except for financial instruments which are accounted for as set out in note 3.1.

2.2 Statement of compliance

The financial statements are prepared in accordance with IFRS Accounting Standards issued by the International Accounting Standards Board ("IASB") and Financial Reporting Pronouncements issued by the Financial Reporting Standards Council, and the requirements of the Collective Investment Schemes Control Act No 45 of 2002 (CISCA), in order to meet the requirements of the Trust Deed approved by the Financial Services Conduct Authority.

2.3 Functional and presentation currency

These financial statements are presented in South African Rand (ZAR) which is the Fund's presentation currency. The functional currency of the Fund is the United States Dollar (USD). All financial information presented has been rounded to the nearest Rand.

2.4 Significant judgements and sources of estimation uncertainty

Preparing annual financial statements in conforming with IFRS Accounting Standards requires estimates and assumptions that affect reported amounts and related disclosures. Significant judgement was applied by the directors of the Manager with regards to the functional currency as detailed below.

The Fund invests only in listed equity securities and measures these instruments at fair value through profit or loss using quoted prices in active markets. Accordingly, the valuation of the investment portfolio does not involve significant management judgement or estimation uncertainty as at the reporting date.

Determination of functional currency

Functional currency is the currency of the primary economic environment in which the Fund operates. If indicators of the primary economic environment are mixed, then management uses its judgement to determine the functional currency that most faithfully represents the economic effect of the underlying transactions, events and conditions. The Fund is administered and managed in United States Dollar. Accordingly management has determined that the functional currency of the Fund is United States Dollar.

3. Accounting policies

The financial statements incorporate the principal accounting policies set out below which is consistent with those adopted in the previous financial year.

3.1 Financial instruments

(i) Classification

The Fund classifies financial assets and financial liabilities into the following categories:

- Financial assets at fair value through profit or loss;
- Financial assets at amortised cost;
- Financial liabilities measured at amortised cost; and
- Financial liabilities designated at fair value through profit or loss

Classification depends on the purpose for which the financial instruments were obtained / incurred and takes place at initial recognition.

Financial assets and liabilities at fair value through profit or loss

The Fund classifies their investments based on both the Fund's business model for managing those financial assets and the contractual cash flow characteristics of the financial assets. The portfolio of financial assets are managed and performance is evaluated on a fair value basis. The Fund is primarily focused on fair value information and uses that information to assess the assets' performance and to make decisions. The Funds have not taken the option to irrevocably designate any equity securities at fair value through other comprehensive income. The contractual cash flows of the Fund's debt securities are solely principal and interest, however, these securities are neither held for the purpose of collecting contractual cash flows nor held both for collecting contractual cash flows and for sale. The collection of contractual cash flows is only incidental to achieving the Fund's business model's objective. Consequently, all investments are measured at fair value through profit or loss.

Based on the principle of eliminating an accounting mismatch in the financial statements, net assets attributable to holders of redeemable securities are designated to be measured at fair value through profit or loss. The Fund's accounting policy is described in note 3.9 below.

Financial assets and liabilities at amortised cost

Financial assets at amortised cost include dividends receivable, other receivables (including sales transactions awaiting settlement) and cash and cash equivalents. Financial liabilities at amortised cost include accrued expenses, distributions payable and other payables (including purchases transactions awaiting settlement).

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

3. Accounting policies (continued)

3.1 Financial instruments (continued)

(ii) Recognition and initial measurement

Financial assets and liabilities measured at fair value through profit or loss are recognised initially on the trade date, which is the date that the Fund becomes a party to the contractual provisions of the instrument. Other financial assets and liabilities are recognised on the date they are originated.

Financial assets and financial liabilities measured at fair value through profit or loss are recognised initially at fair value, with transaction costs recognised in profit or loss. Financial assets and financial liabilities not measured at fair value through profit or loss are recognised initially at fair value plus transaction costs that are directly attributable to their acquisition or issue.

(iii) Subsequent measurement

After initial measurement, the Fund measures financial instruments which are classified as at FVPL at fair value. Subsequent changes in the fair value of those financial instruments are recorded in profit or loss as on a net basis in the statement of profit or loss and other comprehensive income. Dividends earned or paid on these instruments are recorded separately in dividend income or expense in profit or loss in the statement of profit or loss and other comprehensive income.

Financial liabilities, other than those classified as at FVPL, are measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the debt instruments are derecognised or impaired, as well as through the amortisation process.

Amortised cost measurement

The amortised cost of a financial asset or financial liability is the amount at which the financial asset or financial liability is measured at initial recognition, minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between the initial amount recognised and the maturity amount, minus any reduction for impairment.

Fair value measurement

Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction on the measurement date. When available, the Fund measures the fair value of an instrument using quoted prices in an active market for that instrument. A market is regarded as active if quoted prices are readily and regularly available and represent actual and regularly occurring market transactions on an arm's length basis. The Fund does not apply valuation techniques, overlays or management adjustments to quoted prices for listed equity securities.

Investments in other open-ended funds are recorded at the quoted net asset value per unit as reported by the managers of such funds.

The Fund uses the weighted average method to determine realised gains and losses on derecognition. All changes in fair value, other than interest and dividend income and expense, are recognised in profit or loss as part of net gain / (loss) on financial instruments.

(iv) Derecognition

A financial asset (or, where applicable, a part of a financial asset or a part of a group of similar financial assets) is derecognised where the rights to receive cash flows from the asset have expired, or the Fund has transferred its rights to receive cash flows from the asset, or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a pass-through arrangement and the Fund has:

- (a) Transferred substantially all of the risks and rewards of the asset, or
- (b) Neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Fund has transferred its right to receive cash flows from an asset (or has entered into a pass-through arrangement), and has neither transferred nor retained substantially all of the risks and rewards of the asset nor transferred control of the asset, the asset is recognised to the extent of the Fund's continuing involvement in the asset. In that case, the fund also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the fund has retained.

The Fund derecognises a financial liability when the obligation under the liability is discharged, cancelled or expired.

(v) Impairment of financial assets

Financial assets measured at amortised cost consists of dividends receivable that matures within three months and cash and cash equivalents that are held with reputable financial institutions.

Expected credit losses on financial assets at amortised cost are assessed and recognised in accordance with the simplified approach.

3.2 Investment income

Investment income comprises:

- Interest income earned on cash and cash equivalents;
- Income adjustment on creation of units (at the time of creation, this relates to the equalisation component that represents the income portion attributable to the net asset value at the time that is payable by the creating party); and
- Dividends from listed equities held at fair value through profit or loss.

3.3 Interest income

Interest income is recognised in profit or loss using the effective interest method taking into account the expected timing and amount of cash flows.

3.4 Dividend income

Dividend income is recognised when the right to receive the payment is established. This is usually the ex-dividend date for quoted equities.

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

3. Accounting policies (continued)

3.5 Foreign currency transactions

Foreign currency transactions are those transactions that are not denominated in the functional currency (USD). Transactions in foreign currencies are translated to USD at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into USD at the exchange rate ruling at that date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at historical cost are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated into USD at the exchange rate ruling at the date that the fair value was determined.

Foreign currency differences arising on translation are recognised in profit or loss. Where the average exchange rate approximates the exchange rate used at the date of the transaction the average exchange rate has been applied.

Translation into presentation currency of South African Rand (Rand)

Assets and liabilities are translated from the Fund's functional currency to Rand using the exchange rates at the reporting date. The income and expense items are translated to Rand using the exchange rate at the dates of the transaction.

Differences arise from the translation into Rand because of:

- Exchange rates used to translate the opening value of the investments in the beginning of the year;
- Exchange rates used to translate transactions during the year, including income and expenses and new investments; and
- Exchange rate used to translate the closing carrying amount of investments at the end of the year.

These differences have an opposite adjustment effect on the value of the redeemable securities liability, which equals the net asset value of the Fund. The differences that result from the foreign exchange translation is reflected as 'Translation of functional currency to ZAR' and 'Foreign currency translation adjustments attributable to holders of redeemable securities' in the Statement of profit or loss and other comprehensive income and in the Statement of changes in net assets attributable to holders of redeemable securities respectively.

3.6 Withholding tax

Withholding tax levied on dividends received is recognised as a tax expense in the period in which the related dividend income is recognised. This tax reduces the amount available for distribution to investors.

3.7 Taxation

Under the current system of taxation in South Africa, income is taxed in the hands of the investor if distributed within 12 months failing which the income will be deemed to be received by and accrued to the Fund and will be taxed in the Fund.

No deferred tax is recognised, as the Fund will not have tax consequences when the assets are sold or the liabilities settled. All tax consequences will be in the hands of the investors.

Foreign dividend income is reflected gross of withholding tax (WHT). The income is passed on to the investors net of WHT.

3.8 Expenses

Expenses are recognised in profit or loss as incurred. Management fees are calculated on a daily basis at an agreed percentage of the assets under management.

3.9 Redeemable securities

All redeemable securities issued by the Fund provide investors with the right to require redemption for cash or *in specie* at the value proportionate to each investor's share. The securities are redeemable at any time at the option of the security holder and are therefore classified as financial liabilities.

The fair value of redeemable securities is measured at the redemption amount that is payable in cash and securities representing each investor's equal undivided and vested interest in the assets as a whole, subject to liabilities as defined by the Trust Deed. In accordance with the Trust Deed and CISCA, the Fund is contractually obliged to redeem securities at the NAV.

3.10 Creations and redemptions

Investors can acquire Sygnia Itrix securities by trading on the Johannesburg Stock Exchange (JSE). These purchases will be made at the current market price of the securities plus a brokerage fee that is negotiable with the broker and any additional transaction costs applicable to such a trade.

The cash subscription price and the number of Sygnia Itrix securities to be issued to an investor for cash will be determined by the amount which the investor invests (net of transaction costs) and will be a function of the *pro rata* cost to the Fund of acquiring the underlying basket of securities.

Investors may sell securities by trading on the JSE.

Security prices are determined by reference to the net assets of the Fund divided by the number of securities in issue. For security pricing purposes, net assets are determined using the last reported trade price for securities. These prices may differ from the market price quoted on the JSE.

3.11 Equalisation component of a redeemable security

At the time of creation/redemption, this component represents the income portion attributable to the net asset value at the time and is payable by the creating party or paid to the redeeming party.

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

3. Accounting policies (continued)

3.12 Distributions

In accordance with the Trust Deed, the Fund distributes its distributable income and any other amounts determined by the management company to security holders in cash. The distributions are payable bi-annually.

Distributions payable on redeemable securities are recognised in profit or loss in the period in which they have accrued.

3.13 Operating segments

Sygnia Itrix Health Innovation Actively Managed ETF offers only one product, being the specific exchange traded fund, tracking the specific identified index. Information regarding the results of the reportable segment is disclosed in the financial statements as currently set out, thus no further IFRS 8 disclosure is required.

3.14 New Standards and Interpretations

Standards and interpretations not yet effective

At the date of authorisation of these financial statements, the following standards and interpretations that impact the Fund were in issue, but not yet effective:

IFRS 18 - Presentation and Disclosure in Financial Statements - Effective for annual periods beginning on or after 1 January 2027

IFRS 18 replaces IAS 1 Presentation of Financial Statements and includes requirements for all entities applying IFRS Accounting Standards for the presentation and disclosure of information in financial statements.

During the current year, the directors of the Manager has considered the impact of all standards, amendments and interpretations in issue, but not yet effective, and does not believe that there are any material impacts to be noted as at the date of this report. A continual effort will be made to assess whether there is a need to revisit this determination.

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

	2025 R	2024 R
4. Financial assets at fair value through profit or loss		
Listed equity securities	211 530 153	559 540 966
Foreign exchange traded fund	11 145 883	-
	222 676 036	559 540 966

5. Sygnia Itrix Health Innovation Actively Managed ETF redeemable securities

5.1 Sygnia Itrix Health Innovation Actively Managed ETF redeemable securities in issue

	2025 Number	2024 Number
Total redeemable securities in issue	7 269 618	18 069 618

In terms of the Trust Deed and CISCA, the Fund would be required to pay the net asset value attributable to investors on redemption of securities. Vested income beneficiaries include all holders of Sygnia Itrix Health Innovation Actively Managed ETF redeemable securities.

5.2 Creations and redemptions

	2025 Units	2024 Units	2025 R	2024 R
Creation of redeemable securities	-	3 400 000	-	111 725 064
Redemption of redeemable securities	(10 800 000)	(7 398 887)	(315 809 635)	(233 210 592)

5.3 Distributions

The Fund effects bi-annual distributions. All distributions are made from the income of the Fund.

During the year under review the following distributions were effected by the Fund:

	2025 R	2024 R
Declared distributions	(3 157 599)	(6 405 761)
0.16879 rand per security declared June 2025 and paid July 2025	(2 408 551)	
0.17988 rand per security declared June 2024 and paid July 2024		(4 545 380)
0.10304 rand per security declared December 2025 and paid January 2026	(749 048)	
0.10296 rand per security declared December 2024 and paid January 2025		(1 860 381)
Total distribution expense for the year	(3 157 599)	(6 405 761)

5.4 Quarterly review of Sygnia Itrix Health Innovation Actively Managed ETF Redeemable Security Prices (cents per security)

Quarter ended:	High cents	Low cents	Close cents
31 March 2025	3 283	3 085	3 124
30 June 2025	3 166	2 835	2 903
30 September 2025	2 956	2 776	2 888
31 December 2025	3 240	2 956	3 077
31 March 2024	3 426	3 051	3 380
30 June 2024	3 407	3 177	3 273
30 September 2024	3 474	3 203	3 229
31 December 2024	3 298	3 018	3 110

5.5 Foreign currency translation adjustments attributable to holders of redeemable securities

	2025 R	2024 R
Spot rate as at 31 December (USD)	16.57	18.87
Average rate for the financial year (USD)	17.87	18.33
<i>Arising from:</i>		
Translation of opening balance to year end closing spot rate	(68 247 250)	21 424 942
Translation of creations during the year from the rate at the date of the transaction to the year end closing spot rate	-	789 878
Translation of redemptions during the year from the rate at the date of transaction to the year end closing spot rate	22 361 986	(9 802 093)
Translation of net income earned at average rates during the year to the year end closing spot rate	423 011	761 152
Total effect of foreign currency translation adjustment	(45 462 253)	13 173 879

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

	2025 R	2024 R
6. Trade and other receivables		
Dividends receivable	139 222	363 389
	<u>139 222</u>	<u>363 389</u>

Refer to credit risk Note 15 for further disclosure.

7. Cash and cash equivalents

Standard Bank - South African Rand	14 636	61 349
The Bank of New York	1 135 890	2 370 732
	<u>1 150 526</u>	<u>2 432 081</u>

The cash and cash equivalents held with The Bank of New York includes the following foreign currencies held, translated to South African Rand at the spot exchange rate at year end:

	Functional Currency (USD)		Presentation Currency (ZAR)	
	2025	2024	2025	2024
Australian Dollar	-	(1)	-	(19)
Japanese Yen	(2)	6	(33)	113
Great British Pounds	32	(52)	530	(981)
United States Dollar	68 521	125 682	1 135 393	2 371 619
			<u>1 135 890</u>	<u>2 370 732</u>

Cash and cash equivalents comprise balances with banks. The Standard Bank of South Africa Limited's credit rating for the long-term local currency and foreign currency deposits is BB-. Risk on South African banks is considered negligible as all cash deposits are guaranteed by the SA Reserve Bank and banks are financially sound. The long term issuer default rating for the Bank of New York Mellon, as Global custodian, is AA.

	2025 R	2024 R
8. Trade and other payables		
Distributions payable	749 048	1 860 381
Management fees payable	95 755	250 365
Custody fees Payable	126 779	74 153
Listing fees payable	28 281	70 638
Strate fees payable	26 799	28 111
Withholding tax payable	19 962	83 464
	<u>1 046 624</u>	<u>2 367 112</u>

Trade and other payables are short term in nature and are settled regularly.

9. Net gain/(loss) on financial assets at fair value through profit or loss

Realised (loss)/gain on financial assets at fair value through profit or loss	(3 369 594)	18 037 965
Unrealised gain/(loss) on financial assets at fair value through profit or loss	27 645 181	(20 425 047)
	<u>24 275 587</u>	<u>(2 387 082)</u>

10. Investment income

Income on financial assets at fair value through profit or loss:

Dividend income	7 602 085	13 005 998
Income adjustment on creation of units	-	374 545
Interest income	26 279	60 388
	<u>7 628 364</u>	<u>13 440 931</u>

11. Management and administrative expenses

Management and administrative expenses include:

Income adjustment on cancellation of units	954 887	676 316
Bank charges	1 223	1 299
Brokerage expense	20 043	51 451
Management fees	1 999 320	3 877 786
Custody fees	114 513	34 036
Strate fees	55 290	46 384
Listing fees	40 306	92 932
	<u>3 185 582</u>	<u>4 780 204</u>

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

	2025 R	2024 R
12. Cash utilised in operations		
Profit/(loss) for the year before tax	25 651 064	(267 243)
<i>Adjusted for non-cash and separately disclosable items:</i>		
Dividend income	(7 602 085)	(13 005 998)
Net (gain)/loss on financial assets at fair value through profit or loss	(24 275 587)	2 387 082
Foreign exchange (gain)/loss	(90 294)	135 127
Income adjustment on creation of units	-	(374 545)
Income adjustment on cancellation of units	954 887	676 316
Management fees	1 999 320	3 877 786
Distributions declared	3 157 599	6 405 761
Interest income	(26 279)	(60 388)
<i>Working capital changes:</i>		
Increase in trade and other payables	8 957	106 458
	(222 418)	(119 644)
13. Purchases and sales of index constituents		
Purchases of index constituents	(105 698 606)	(212 837 036)
Sales of index constituents	421 376 870	334 577 809
	315 678 264	121 740 773
14. Related parties		

Related parties include the Manager, Sygnia Itrix (RF) Proprietary Limited, in its capacity as the management company of the Fund. The ultimate holding company of the Manager is Sygnia Limited. There were no transactions with the ultimate holding company.

The following related party balances and transactions occurred during the year:

Trade and other payables

– Management fee payable	95 755	250 365
--------------------------	--------	---------

Expenses

– Management fee expense	1 999 320	3 877 786
--------------------------	-----------	-----------

The management fee expense is calculated on a daily basis at 44 basis points excluding VAT (2024: 44 basis points excluding VAT) of net asset value per annum. There were no material transactions with The Standard Bank of South Africa Limited in its capacity as Trustee.

Outstanding balances will be settled in the ordinary course of business.

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

15. Financial risk management

The Fund has exposure to the following risks from its use of financial instruments:

- Credit risk
- Currency risk
- General market risk
- Investment risk
- Liquidity risk
- Operational risk
- Secondary trading risk

The objectives for managing the risks associated with financial instruments held for investment purposes as well as a brief description of the relevant risks and methods adopted to mitigate these risks are outlined in more detail below. The Fund is an underlying portfolio of the Sygnia Itrix Collective Investment Scheme which is regulated by CISC. In terms of CISC the Manager must appoint a Trustee.

The primary objective of Sygnia Itrix Health Innovation Actively Managed ETF is to achieve long-term capital appreciation by investing in a diversified portfolio of companies which have direct or indirect exposure to the healthcare sector. The fund aims to outperform its benchmark index, the Solactive Developed Markets Healthcare 150 Index, through active management and strategic allocation. The ETF will employ an active management strategy, leveraging the expertise of portfolio managers to select healthcare stocks that exhibit strong growth potential.

The fund has a high risk profile, as it is predominantly in global equities, which combines both equity market and currency risks. Effective exposure of the fund invested outside South Africa will always be above 80% and is affected by, among other factors, general market risk, exchange rate risk, interest rate risk, liquidity risk and legal and regulatory risk. The portfolio aims to achieve its investment objectives, whilst recognising that there will be significant short-term volatility and aims to protect capital over the medium to long term.

Management monitors compliance with CISC requirements and reports are submitted to the Financial Services Conduct Authority. Capital adequacy requirements as required by CISC are maintained by the Manager of the Fund. Daily pricing of the Fund is publicly available.

The Manager's Audit Committee oversees management's compliance with the Fund's Risk Management Framework in relation to the risks faced by the Fund.

Credit risk

The Fund could be exposed to credit risk as a result of a counterparty to a transaction failing to meet its contractual obligations. This could arise primarily from the Fund's cash held in bank accounts. Credit risk is assessed as minimal due to the following reasons:

- The nature of the Fund is to invest in listed shares, so cash balances are kept at a low level;
- The banks at which the Fund banks, namely The Standard Bank of South Africa and The Bank of New York, both have high credit ratings; and
- There are short settlement periods involved relating to unsettled transactions, and this is monitored on a daily basis as part of the Fund administration process.

The maximum credit exposure at the statement of financial position is equal to the carrying amounts of the following assets disclosed on the face of the Fund's statement of financial position:

- Trade and other receivables
- Cash and cash equivalents

None of these assets are impaired.

Currency risk

The Fund invests in listed equity shares denominated in various currencies, with the functional currency of the Fund being United States Dollar. As the Fund's net asset values are reported in Rand, movements in the United States Dollar exchange rates in relation to the Rand would cause volatility in the Fund's Rand investment balances and unit prices. This is merely as a result of translation from the functional currency to the presentation currency, and is not presented in the sensitivity analysis below. The fund is, however, exposed to foreign currency risk on investments that are denominated in a currency other than United States Dollar.

The table below summarises the Fund's non-monetary investments denominated in a currency other than United States Dollar, and illustrates the Fund's exposure to the applicable foreign currencies and the effect of a change in exchange rates on profit or loss for the year, as indicated. The sensitivity analysis is prepared with all other variables held constant, and is based on the balances at year end taking into account the reasonable possible changes in the next 12 months. The actual results may differ from the sensitivity analysis and the difference could be material. The disclosure provides information on the risks to which unit holders are exposed and is not indicative of future performance.

Currency exposure	2025 USD Functional currency	2024 USD Functional currency	2025 R Presentation currency	2024 R Presentation currency
Australian Dollar	136 021	394 634	2 253 863	7 446 743
Swiss Franc	1 108 225	1 924 149	18 363 282	36 308 696
Danish Krone	289 922	1 111 958	4 804 014	20 982 638
Euro	614 689	1 135 119	10 185 402	21 419 703
Great British Pound	663 640	1 115 167	10 996 509	21 043 199
Hong Kong Dollar	26 279	17 230	435 438	325 126
Israeli Shekel	55 118	87 399	913 307	1 649 214
Japanese Yen	484 505	1 143 818	8 028 249	21 583 841
New Zealand Dollar	18 170	45 308	301 072	854 955
Swedish Krona	10 794	26 887	178 856	507 367

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

15. Financial risk management (continued)

Currency risk (continued)

Reasonable possible shift in currency rate in relation to USD	2025	Increase		Decrease	
		2025	2024	2025	2024
Presentation currency		R	R	R	R
Australian Dollar	6%	135 232	(135 232)	6%	446 805 (446 805)
Swiss Franc	10%	1 836 328	(1 836 328)	6%	2 178 522 (2 178 522)
Danish Krone	8%	384 321	(384 321)	5%	1 049 132 (1 049 132)
Euro	8%	814 832	(814 832)	5%	1 070 985 (1 070 985)
Great British Pound	5%	549 825	(549 825)	6%	1 262 592 (1 262 592)
Hong Kong Dollar	1%	4 354	(4 354)	1%	3 251 (3 251)
Israeli Shekel	6%	54 798	(54 798)	5%	82 461 (82 461)
Japanese Yen	6%	481 695	(481 695)	10%	2 158 384 (2 158 384)
New Zealand Dollar	5%	15 054	(15 054)	6%	51 297 (51 297)
Swedish Krona	11%	19 674	(19 674)	8%	40 589 (40 589)

Reasonable possible shift in currency rate in relation to USD	2025	Increase		Decrease	
		2025	2024	2025	2024
Functional currency		USD	USD	USD	USD
Australian Dollar	6%	8 161	(8 161)	6%	23 678 (23 678)
Swiss Franc	10%	110 822	(110 822)	6%	115 449 (115 449)
Danish Krone	8%	23 194	(23 194)	5%	55 598 (55 598)
Euro	8%	49 175	(49 175)	5%	56 756 (56 756)
Great British Pound	5%	33 182	(33 182)	6%	66 910 (66 910)
Hong Kong Dollar	1%	263	(263)	1%	172 (172)
Israeli Shekel	6%	3 307	(3 307)	5%	4 370 (4 370)
Japanese Yen	6%	29 070	(29 070)	10%	114 382 (114 382)
New Zealand Dollar	5%	908	(908)	6%	2 718 (2 718)
Swedish Krona	11%	1 187	(1 187)	8%	2 151 (2 151)

General market risk

Market risk arises from changes in market conditions, including interest rates, equity prices, and other economic factors. The issuer manages market risk through strategic asset allocation, risk diversification, and ongoing monitoring of market developments. Stress testing and scenario analysis are conducted to assess the potential impact of adverse market conditions.

The table below illustrates the effect of possible changes in the fair value of investments for price risks on profit or loss for the year. The sensitivity analysis is prepared with all other variables held constant, and is based on the balances at year-end taking into account the reasonable possible changes in the next 12 months. The actual results may differ from the sensitivity analysis below and the difference could be material. The disclosure provides information on the risks to which unit holders are exposed and it is not indicative of future performance. The movement has been disclosed for an average respective benchmark return since the launch of the fund. Management considered this to be a reasonable change in the market based on the current economic environment.

Average benchmark return	2025		2024	
	Increase in average benchmark return	Decrease in average benchmark return	Increase in average benchmark return	Decrease in average benchmark return
	R	R	R	R
4% (2024: 1%)	8 916 766	(8 916 766)	5 599 693	(5 599 693)

Investment risk

Investment risk is inherent in the fund's portfolio of securities held and results from market volatility, issuer-specific factors, and other uncertainties. The Collective Investment Schemes Control Act has strict and specific regulations as to which instruments may or may not be held. The fund is also governed by the Trust Deed and its supplemental Trust Deed, which commits it to a specific investment objective. Each Trust Deed's investment objective is further refined into an investment mandate which requires the investment manager to manage the fund in accordance with the specified mandate. Daily checks are performed by the independent trustee/custodian as well as the compliance functions of the management company and each appointed investment manager to ensure compliance with investment mandates and limitations specified in the respective Trust Deeds and the regulations determined under the Collective Investments Scheme Control Act.

The Fund's exposure to climate-related and transition risks is indirect through the listed equity issuers included in the Index. The Fund does not hold non-financial assets and does not apply climate-related valuation overlays; any market assessment of these risks is reflected in the quoted prices of the underlying constituents.

Liquidity risk

Liquidity risk refers to the risk that the fund may not be able to sell a security at its fair market value due to a lack of marketability or the fund is not able to meet its financial obligations, such as income distributions, to investors when they fall due. The liquidity risk is managed by the fact that the fund invests in highly liquid, listed equity shares only. The turnaround time to liquidate such listed equity shares is 1 day, which is the trade cycle of the US market, and 2 days in Other markets.

The approach to managing liquidity risk is to ensure that the Fund would be able to pay management fees and distributions to investors on a bi-annual basis. All amounts due to investors are settled prior to settlement of the management fees due to the Manager. All distributions are approved by the Trustee and calculated by the Management Company.

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

15. Financial risk management (continued)

Liquidity risk (continued)

Sygnia Itrix Health Innovation Actively Managed ETF redeemable securities are listed instruments. They are bought and sold on the JSE through a JSE member. The redeemable security can be sold to the Manager which is obliged to buy them from the investor.

Contractual maturity	2025	2024
	R	R
	Less than	Less than
	6 months	6 months
Trade and other payables	1 046 624	2 367 112
Net assets attributable to holders of redeemable securities*	222 919 160	559 969 324
	223 965 784	562 336 436

* Net assets attributable to holders of redeemable securities are payable on demand.

Operational risk

Operational risk includes the risk of losses resulting from inadequate or failed internal processes, systems, or external events. The issuer has established robust operational controls, internal procedures, and risk management frameworks to mitigate operational risk. Regular audits and reviews are conducted to assess operational effectiveness and ensure compliance with regulatory requirements.

If the computer facilities or other facilities of the JSE malfunction, calculation and trading in the Fund's redeemable securities may be suspended for a period of time.

Secondary trading risk

Sygnia Itrix Health Innovation Actively Managed ETF shares are listed securities and they are bought and sold on the JSE secondary market through a JSE member. Secondary trading risk refers to the risk associated with trading the fund's shares on the JSE. Market makers will attempt to maintain a high degree of liquidity through continuously offering to buy and sell Sygnia Itrix redeemable securities at prices around the NAV of the redeemable share thereby ensuring tight buy and sell spreads. Under normal circumstances and conditions, the investor will be able to buy or sell Sygnia Itrix Health Innovation Actively Managed ETF redeemable securities from the market makers.

There can be no guarantee that the redeemable securities will remain listed on the JSE. Despite the presence of market makers, the liquidity of the redeemable securities cannot be guaranteed. Redeemable securities may trade at a discount or premium to their NAV. Any termination of a listing would be subject to the JSE's listing requirements.

16. Fair value

The fair values of all financial instruments approximate the carrying values reflected in the statement of financial position.

Fair value measurements recognised in the statement of financial position

Fair value measurement defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal market, or the most advantageous markets at the current market conditions. Fair value is an exit price regardless of whether that price is directly observable or estimated using another valuation technique.

The following table provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which the fair value is observable.

Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Instrument	Valuation Technique			Main Assumption
	Level 1	Level 2	Level 3	
Listed Securities	Market price quoted on the securities exchange			Not applicable – prices are publicly available
Items at fair value:				
	Level 1	Level 2	Level 3	Total
	R	R	R	R
31 December 2025				
Financial assets				
Equity instruments at fair value through profit or loss	222 676 036	-	-	222 676 036
Financial liabilities				
Net assets attributable to holders of redeemable securities	-	222 919 160	-	222 919 160

Sygnia Itrix Health Innovation Actively Managed Exchange Traded Fund

Notes to the financial statements

for the year ended 31 December 2025

16. Fair value (continued)

Items at fair value:

31 December 2024	Level 1 R	Level 2 R	Level 3 R	Total R
Financial assets				
Equity instruments at fair value through profit or loss	559 540 966	-	-	559 540 966
Financial liabilities				
Net assets attributable to holders of redeemable securities	-	559 969 324	-	559 969 324

Investments whose values are based on quoted market prices in active markets, and therefore classified within level 1, include active listed equities. Net assets attributable to holders of redeemable securities, classified within level 2, are based on the quoted net asset value per unit. There are no financial instruments classified within level 3 and transfers did not occur between levels in the period under review.

As the Fund's investments are valued using market price quoted on the securities exchange, the Fund is not exposed to significant valuation uncertainty arising from unobservable inputs at the reporting date.

17. Subsequent events

No other matter or circumstance of which the directors of Sygnia Itrix (RF) Proprietary Limited are aware has arisen since the end of the financial year which is not dealt with in the financial statements that has a significant effect or may have a significant effect on the performance or financial position of the Fund.

18. Going concern

The annual financial statements have been prepared on the basis of accounting policies applicable to a going concern. The basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of the business. The manager is not aware of any material uncertainties related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern.